Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.35 |
| ▸ | MMP1 | P03956 | 8/20 | 0.34 |
| ▸ | MMP2 | P08253 | 8/20 | 0.34 |
| ▸ | MMP9 | P14780 | 8/20 | 0.34 |
| ▸ | MMP8 | P22894 | 8/20 | 0.34 |
| ▸ | MMP13 | P45452 | 8/20 | 0.34 |
| ▸ | CA1 | P00915 | 6/20 | 0.34 |
| ▸ | F2 | P00734 | 3/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10438310 | 0.93 | F2 (0.33) | CA2MMP1MMP2MMP9MMP8 | |
| SCHEMBL10438316 | 0.93 | MMP1 (0.33) | CA2MMP1MMP2MMP9MMP8 | |
| SCHEMBL29457183 | 0.93 | MMP1 (0.33) | CA2MMP1MMP2MMP9MMP8 | |
| SCHEMBL10438318 | 0.93 | MMP1 (0.33) | CA2MMP1MMP2MMP9MMP8 | |
| SCHEMBL5168754 | 0.93 | F2 (0.33) | CA2MMP1MMP2MMP9MMP8 | |
| SCHEMBL5152620 | 0.89 | CA1 (0.34) | CA2MMP1MMP2MMP9MMP8 | |
| SCHEMBL9326862 | 0.85 | CA2 (0.32) | CA2MMP1MMP2MMP9MMP8 | |
| SCHEMBL29910639 | 0.84 | CA2 (0.43) | CA2MMP1MMP2MMP9MMP8 | |
| SCHEMBL2888010 | 0.83 | MMP1 (0.33) | CA2MMP1MMP2MMP9MMP8 | |
| SCHEMBL10358857 | 0.83 | MMP1 (0.33) | CA2MMP1MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240159781-A1 | SANDWICH ASSAY FOR SMALL MOLECULES | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11913965-B2 | Sandwich assay for small molecules | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230160880-A1 | PRETREATMENT AGENT IN NON-AGGLUTINATION ASSAYS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-11592439-B2 | Pretreatment agent in non-agglutination assays | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| EP-4036572-A1 | METHODS FOR DETECTION OF IMMUNOSUPPRESSANT DRUGS | Siemens Healthcare Diagnostics Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| US-11377483-B2 | Sandwich assay design for small molecules | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2022-07-05 | — | — | US | disclosed |
| EP-2176658-B1 | METHODS FOR DETECTION OF IMMUNOSUPPRESSANT DRUGS | SIEMENS HEALTHCARE DIAGNOSTICS INC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20210199677-A1 | SANDWICH ASSAY FOR SMALL MOLECULES | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2021-07-01 | — | — | US | disclosed |
| EP-3234607-B1 | SANDWICH ASSAY DESIGN FOR SMALL MOLECULES | SIEMENS HEALTHCARE DIAGNOSTICS INC (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210087255-A1 | SANDWICH ASSAY DESIGN FOR SMALL MOLECULES | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2021-03-25 | — | — | US | disclosed |
| WO-2011163340-A1 | REDUCTION IN FALSE RESULTS IN ASSAY MEASUREMENTS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-8084223-B2 | Detection of false results in assays | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110136136-A1 | Methods For Detection Of Hydrophobic Drugs | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7910378-B2 | Methods for detection of hydrophobic drugs | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100240073-A1 | DETECTION OF FALSE RESULTS IN ASSAYS | SIEMENS HEALTHCARE DIAGNOSTICS INC., A CORPORATION OF CALIFORNIA (US) | 2010-09-23 | — | — | US | disclosed |
| US-7790401-B2 | Methods for detection of immunosuppressant drugs | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2217926-A1 | METHODS FOR DETECTION OF HYDROPHOBIC DRUGS | Siemens Healthcare Diagnostics Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009079374-A1 | METHODS FOR DETECTION OF HYDROPHOBIC DRUGS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| US-20090155929-A1 | METHODS FOR DETECTION OF HYDROPHOBIC DRUGS | SIEMENS HEALTHCARE DIAGNOSTICS INC., A CORPORATION OF CALIFORNIA (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090042223-A1 | METHODS FOR DETECTION OF IMMUNOSUPPRESSANT DRUGS | DADE BEHRING INC., A CORPORATION OF DELAWARE (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377483-B2 | Sandwich assay design for small molecules | SHBG, SERPINA6, SPR | CA2 3805/4885MMP1 3366/4885MMP2 1732/4885 |
| US-20210087255-A1 | SANDWICH ASSAY DESIGN FOR SMALL MOLECULES | SHBG, SERPINA6, SPR | CA2 3805/4885MMP1 3366/4885MMP2 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.